Key result
In silico predictive tools showed poor accuracy for 126 CLCN1 variants compared to cell-based electrophysiology, with the highest accuracy obtained by MutationTaster (84.58%) and REVEL (82.54%).
Why the study?
The clinical value of in silico predictive tools for variant pathogenicity is often unclear because they are rarely validated against robust functional assays.
How accurate are in silico predictive tools compared to functional assays for determining the pathogenicity of CLCN1 variants in myotonia congenita?
Observational (n=126)
How accurate are in silico predictive tools compared to functional assays for determining the pathogenicity of CLCN1 variants in myotonia congenita?
Current in silico predictive tools for CLCN1 variants lack sufficient specificity for reliable clinical use, highlighting the need for improved predictive models.
Answers are grounded in this paper and cite their sources.
Caution against sole reliance on in silico tools for variant classification; leaves open need for functional validation in clinical genetics.
Accurate determination of the pathogenicity of missense genetic variants of uncertain significance is a huge challenge for implementing genetic data in clinical practice. In silico predictive tools are used to score variants' pathogenicity. However, their value in clinical settings is often unclear, as they have not usually been validated against robust functional assays. We compared nine widely used in silico predictive tools, including more recently developed tools (EVE and REVEL) with detailed cell-based electrophysiology, for 126 CLCN1 variants discovered in patients with the skeletal muscle channelopathy myotonia congenita. We found poor accuracy for most tools. The highest accuracy was obtained with MutationTaster (84.58%) and REVEL (82.54%). Both of these scores showed poor specificity, although specificity was better using EVE. Combining methods based on concordance improved performance overall but still lacked specificity. Our calculated statistics for the predictive tools were different to reported values for other genes in the literature, suggesting that the utility of the tools varies between genes. Overall, current predictive tools for this chloride channel are not reliable for clinical use, and tools with better specificity are urgently required. Improving the accuracy of predictive tools is a wider issue and a huge challenge for effective clinical implementation of genetic data.
No takes yet. Share an insight, caveat, or question.
Vivekanandam et al. (2022) conducted an observational in myotonia congenita (n=126). In silico predictive tools vs. cell-based electrophysiology was evaluated on accuracy. In silico predictive tools showed poor accuracy for 126 CLCN1 variants compared to cell-based electrophysiology, with the highest accuracy obtained by MutationTaster (84.58%) and REVEL (82.54%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: